Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiago Reis Marques

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
Nature Communications|October 5, 2019
Reduced mu opioid receptor availability in schizophrenia revealed with [<sup>11</sup>C]-carfentanil positron emission tomographic ImagingAbhishekh H Ashok, Jim Myers, Tiago Reis Marques, et al.
Medical Hypotheses|August 22, 2009
Obsessive-compulsive disorder as a visual processing impairmentOscar F Gonçalves, Tiago Reis Marques, Nicolás F Lori, et al.
Molecular Psychiatry|December 6, 2019
The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI studyFaith Borgan, Owen O'Daly, Mattia Veronese, et al.
Trends in Psychiatry and Psychotherapy|August 8, 2019
Translation and cross-cultural adaptation of the Arizona Sexual Scale (ASEX) into PortugueseHenrique Prata Ribeiro, Inês Carreira Figueiredo, Joana Vitória-Silva, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2021
Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking studyTiago Reis Marques, Mattia Veronese, David R Owen, et al.
Brain, Behavior, and Immunity|May 22, 2019
The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging studyTarik Dahoun, Marilia A Calcia, Mattia Veronese, et al.
Psychopharmacology|June 27, 2021
Adenosine A<sub>2A</sub> receptor in schizophrenia: an in vivo brain PET imaging studyTiago Reis Marques, Sridhar Natesan, Eugenii A Rabiner, et al.
Molecular Psychiatry|September 1, 2019
The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysisRobert A McCutcheon, Toby Pillinger, Yuya Mizuno, et al.
Neuroimage. Clinical|November 4, 2025
Emotion processing in schizophrenia and its relation to μ-opioid receptor availabilityEkaterina Shatalina, Abhishekh H Ashok, Matthew B Wall, et al.
The Lancet. Psychiatry|November 7, 2016
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programmeDragana Bugarski-Kirola, Nakao Iwata, Snjezana Sameljak, et al.
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
Nature Communications|October 5, 2019
Reduced mu opioid receptor availability in schizophrenia revealed with [<sup>11</sup>C]-carfentanil positron emission tomographic ImagingAbhishekh H Ashok, Jim Myers, Tiago Reis Marques, et al.
Medical Hypotheses|August 22, 2009
Obsessive-compulsive disorder as a visual processing impairmentOscar F Gonçalves, Tiago Reis Marques, Nicolás F Lori, et al.
Molecular Psychiatry|December 6, 2019
The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI studyFaith Borgan, Owen O'Daly, Mattia Veronese, et al.
Trends in Psychiatry and Psychotherapy|August 8, 2019
Translation and cross-cultural adaptation of the Arizona Sexual Scale (ASEX) into PortugueseHenrique Prata Ribeiro, Inês Carreira Figueiredo, Joana Vitória-Silva, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2021
Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking studyTiago Reis Marques, Mattia Veronese, David R Owen, et al.
Brain, Behavior, and Immunity|May 22, 2019
The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging studyTarik Dahoun, Marilia A Calcia, Mattia Veronese, et al.
Psychopharmacology|June 27, 2021
Adenosine A<sub>2A</sub> receptor in schizophrenia: an in vivo brain PET imaging studyTiago Reis Marques, Sridhar Natesan, Eugenii A Rabiner, et al.
Molecular Psychiatry|September 1, 2019
The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysisRobert A McCutcheon, Toby Pillinger, Yuya Mizuno, et al.
Neuroimage. Clinical|November 4, 2025
Emotion processing in schizophrenia and its relation to μ-opioid receptor availabilityEkaterina Shatalina, Abhishekh H Ashok, Matthew B Wall, et al.
The Lancet. Psychiatry|November 7, 2016
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programmeDragana Bugarski-Kirola, Nakao Iwata, Snjezana Sameljak, et al.
Pageof 11